[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633823":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":44,"collaborators":46,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Institut fuer Frauengesundheit","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"High-risk HR+\u002FHER2- early breast cancer patients",null,"High-risk HR+\u002FHER2- early breast cancer patients under abemaciclib therapy",[13],{"name":14,"affiliation":15,"role":16},"Peter A. Fasching, Prof. Dr. med.","Department of Obstetrics and Gynaecology, Uniklinikum Erlangen","STUDY_CHAIR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Sponsor's study office","CONTACT","+49 15739466438","studien@ifg-erlangen.de",[24],{"facility":15,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Erlangen","Bavaria","91054","Germany","DE",{"type":32,"coordinates":33},"Point",[34,35],11.00783,49.59099,{"lat":35,"lon":34},[38,42],{"name":39,"role":20,"phone":40,"phoneExt":10,"email":41},"Study Center","+49 9131 8533572","fk-studienzentrale@uk-erlangen.de",{"name":14,"role":43,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[47,50],{"name":48,"class":49},"Lilly Deutschland GmbH Germany","UNKNOWN",{"name":51,"class":49},"AGO-B Breast Study Group","100633823","patient-relevant-outcomes-improvement-program-in-high-risk-hormone-receptor-positive-hr-breast-cancer-100633823",false,"NCT07531693","Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer","Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer","PROSPER","Inclusion Criteria:\n\n* Femal patients age 18 or older at time of informed consent\n* Confirmed diagnosis of HR+\u002FHER2- early breast cancer (no distant metastasis)\n* Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)\n* Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025\n\nExclusion Criteria:\n\n* Locally advanced or metastatic breast cancer\n* Male patients\n* Patients with contraindication(s) for abemaciclib therapy according to SmPC","FEMALE","18 Years",{"count":63,"type":64},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.",[68],"HR+\u002FHER2- Early Breast Cancer","2026-05-11",{"date":71,"type":72},"2026-05-14","ACTUAL",{"date":74,"type":72},"2026-02-19",{"date":76,"type":64},"2027-03",{"name":5,"class":6},1]